WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018047178) REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/047178    International Application No.:    PCT/IL2017/051011
Publication Date: 15.03.2018 International Filing Date: 08.09.2017
IPC:
A61K 39/395 (2006.01), A61P 25/28 (2006.01), A61P 27/00 (2006.01), C07K 16/28 (2006.01)
Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; at the Weizmann Institute of Science P.O. Box 95 7610002 Rehovot (IL)
Inventors: EISENBACH-SCHWARTZ, Michal; (IL).
BARUCH, Kuti; (IL).
ROSENZWEIG, Neta; (IL)
Agent: SCHWARZ, Mikael; BEN-AMI & ASSOCIATES P.O Box 94 7610002 Rehovot (IL).
SCHWARZ, Mikael; (IL)
Priority Data:
PCT/IB2016/001433 10.09.2016 IB
15/261,945 10.09.2016 US
Title (EN) REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS
(FR) RÉDUCTION DES QUANTITÉS OU DE L'ACTIVITÉ DE CELLULES T RÉGULATRICES SYSTÉMIQUES POUR LE TRAITEMENT DE MALADIE ET DE LÉSION DU SNC
Abstract: front page image
(EN)The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
(FR)La présente invention concerne une composition pharmaceutique comprenant un agent actif qui provoque la réduction du niveau de l'immunosuppression systémique chez un individu, destinée à être utilisée dans le traitement d'une maladie, d'un trouble, d'une affection ou d'une lésion du système nerveux central SNC. Cette composition pharmaceutique est administrée par un régime posologique comprenant au moins un cycle de traitement, chaque cycle de traitement comprenant successivement une session de traitement suivie d'une session intermédiaire sans traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)